Nektar Therapeutics filed a Form 8-K on November 13, 2026, disclosing via Regulation FD that the company held $952.9 million in cash and investments in marketable securities as of September 30, 2026, and expects that balance to extend its cash runway into the third quarter of 2028.

Key Highlights

  • Cash position: Nektar Therapeutics reported $952.9 million in cash and investments in marketable securities as of September 30, 2026.
  • Cash runway: The company expects its cash balance to extend its runway into the third quarter of 2028, consistent with its prior guidance, according to the filing.
  • Clinical milestone: The company cited initial data readouts from Phase 3 ZENITH AD trials in atopic dermatitis, expected in the summer of 2028, as a key milestone covered by the cash runway.
  • Disclosure context: The filing stated the cash position was disclosed in conjunction with third quarter financial results announced on November 12, 2026.
  • Exchange listing: Nektar Therapeutics common stock trades on NASDAQ:NKTR with a par value of $0.0001 per share.

Nektar Therapeutics Discloses Q3 2026 Cash Position and Extended Runway

Nektar Therapeutics filed a Regulation FD current report on November 13, 2026, disclosing financial information furnished in conjunction with its third quarter results announced the prior day, November 12, 2026. According to the filing, the company held $952.9 million in cash and investments in marketable securities as of September 30, 2026.

The filing stated that, "consistent with its prior guidance," the company expects this cash balance to extend its cash runway into the third quarter of 2028, past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis, which are anticipated in the summer of 2028. The company described the cash runway expectation and clinical trial timing as forward-looking statements covered by safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, noting they are "subject to risks, uncertainties and assumptions" and that "actual results could differ materially" from those expressed.

The filing was signed by Elizabeth Zhang, Vice President, Legal, on behalf of Nektar Therapeutics. Per the filing, the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to that section's liabilities, nor is it incorporated by reference in other filings except where expressly specified.

What Was Disclosed

Nektar Therapeutics furnished its September 30, 2026 cash and marketable securities balance of $952.9 million and reiterated guidance that this amount supports operations into the third quarter of 2028, covering anticipated Phase 3 ZENITH AD trial data readouts in atopic dermatitis.